Nkg2d-ig fusion protein for cancer immunotherapy
AssigneeDana-Farber Cancer Institute, Inc.
InventorsGlenn Dranoff, Ryan Sullivan, Matthew Vanneman
Life of this patent
Estimating the term…
Abstract
Methods and compositions for cancer immunotherapy are provided. The methods involve the use of a chimeric molecule (e.g., fusion protein) comprising a dimeric NKG2D portion and an Fc portion, which binds one or more NKG2D ligands. In some embodiments, the molecule further comprises a drug moiety (e.g., an IL15/Ra moiety). The methods disclosed herein are useful for the treatment of cancer that is associated with abnormal expression of one or more NKG2D ligands.
Claims21
1-29. (canceled)
A polypeptide chain comprising:
- (a) a first ligand binding fragment of human NKG2D;
- (b) a second ligand binding fragment of human NKG2D;
- and
- (c) an Fc domain of a human immunoglobulin comprising:
- (i) a CH2 domain;
- and
- (ii) a CH3 domain.
A method of treating an NKG2D ligand expressing cancer, comprising administering to a subject in need thereof a polypeptide chain comprising:
- (a) a first ligand binding fragment of human NKG2D;
- (b) a second ligand binding fragment of human NKG2D;
- and
- (c) an Fc domain of a human immunoglobulin comprising:
- (i) a CH2 domain;
- and
- (ii) a CH3 domain.
A recombinant DNA molecule encoding a polypeptide chain comprising:
- (a) a first ligand binding fragment of human NKG2D;
- (b) a second ligand binding fragment of human NKG2D;
- and
- (c) an Fc domain of a human immunoglobulin comprising:
- (i) a CH2 domain;
- and
- (ii) a CH3 domain.
Dependencies are inferred from the claim text.